JCT  Vol.4 No.1 A , January 2013
Standard Prophylactic Strategy against Peritoneal Dissemination Metastasis in Gastric Cancer
ABSTRACT

Peritoneal carcinomatosis is the most frequent pattern of metastasis and recurrence in patients with gastric cancer, and the prognosis of those patients with peritoneal metastasis is extremely poor. Once peritoneal metastasis is formed, it is extremely difficult to overcome. EIPL (extensive intraoperative peritoneal lavage) is a quite useful and practical adjuvant surgical technique for the gastric cancer patients who are likely to suffer from peritoneal recurrence. EIPL includes 10 times of an extensive shake and wash of abdominal cavity with saline followed by the complete aspiration of the fluid after potentially curative operation, which is supposed to have an amazing cyto-reduction power. The purpose of this article is to review the effect of EIPL on prevention of peritoneal recurrence in the patients with peritoneal free cancer cells and to evaluate its validity as a standard prophylactic strategy against peritoneal recurrence in gastric cancer.


Cite this paper
S. Ikeshima, M. Kuramoto, S. Shimada, K. Yamamoto, T. Masuda, T. Miyata, S. Yoshimatsu, M. Urata and H. Baba, "Standard Prophylactic Strategy against Peritoneal Dissemination Metastasis in Gastric Cancer," Journal of Cancer Therapy, Vol. 4 No. 1, 2013, pp. 99-103. doi: 10.4236/jct.2013.41A014.
References
[1]   D. C. Balfour, “Factor of Significance in the Prognosis of Cancer of the Stomach,” Annals of Surgery, Vol. 105, No. 5, 1937, pp. 733-740. doi:10.1097/00000658-193705000-00009

[2]   Y. Kodera, H. Nakanishi, Y. Yamamura, et al., “Prognostic Value and Clinical Implications of Disseminated Cancer Cells in the Peritoneal Cavity Detected by Reverse Transcriptase-Polymerase Chain Reaction and Cytology,” International Journal of Cancer, Vol. 79, No. 4, 1998, pp. 429-433. doi:10.1002/(SICI)1097-0215(19980821)79:4<429::AID-IJC20>3.0.CO;2-Z

[3]   M. Ikeguchi, S. Matsumoto, S. Yoshida, et al., “Laparoscopic-Assisted Intraperitoneal Chemotherapy for the Patients with Scirrhous Gastric Cancer,” Chemotherapy, Vol. 51, No. 1, 2005, pp. 15-20. doi: 10.1159/000084018

[4]   M. Hiratsuka, T. Iwanaga, H. Furukawa, et al., “Important Prognostic Factors in Surgically Treated Gastric Cancer Patients,” Cancer & Chemotherapy, Vol. 22, No. 5, 1995, pp. 703-708.

[5]   C. H. Yoo, S. H. Noh, D. W. Shin, et al., “Recurrence Following Curative Resection for Gastric Carcinoma,” The British Journal of Surgery, Vol. 87, No. 2, 2000, pp. 236-242. doi:10.1046/j.1365-2168.2000.01360.x

[6]   Y. Kitamura, K. Hayashi, T. Sasagawa, et al., “Pilot Study of S-1 in Patients with Disseminated Gastric Cancer,” Drugs under Experimental and Clinical Research, Vol. 29, No. 3, 2003, pp. 125-130.

[7]   C. Kunisaki, H. Shimada, H. Akiyama, et al., “Therapeutic Outcomes of Continuous Hyperthermic Peritoneal Perfusion against Advanced Gastric Cancer with Peritoneal Carcinomatosis,” Hepato-Gastroenterology, Vol. 53, No. 69, 2006, pp. 473-478.

[8]   C. Kunisaki, H. Shimada, M. Nomura, et al., “Lack of Efficacy of Prophylactic Peritoneal Perfusion on Subsequent Peritoneal Recurrence and Survival in Patients with Advanced Gastric Cancer,” Surgery, Vol. 131, No. 5, 2002, pp. 521-528. doi:10.1067/msy.2002.123769

[9]   S. Ishizoe, F. Maruta, H. Saito, et al., “Efficacy of S-1 for Patients with Peritoneal Metastasis of Gastric Cancer,” Chemotherapy, Vol. 52, No. 6, 2006, pp. 301-307. doi:10.1159/000096002

[10]   L. Suhsien, E. M. Bart, G. M. Stuart, et al., “Results Following Resection for Stage IV Gastric Cancer; Are Better Outcomes Observed in Selected Patients Subgroups?” Journal of Surgical Oncology, Vol. 95, No. 2, 2007, pp. 118-122. doi:10.1002/jso.20328

[11]   Japanese Gastric Cancer Association, “Gastric Cancer Treatment Guidelines,” 3rd Edition, Kanehara, Tokyo, 2010.

[12]   T. Boku, Y. Nakane, T. Minoura, et al., “Prognostic Significant of Serosal Invasion and Free Cancer Cells in Gastric Cancer,” The British Journal of Surgery, Vol. 77, No. 4, 1990, pp. 436-439. doi:10.1002/bjs.1800770425

[13]   E. Bando, Y. Yonemura, Y. Takeshita, et al., “Intraoperative Lavage for Cytological Examination in 1297 Patients with Gastric Carcinoma,” American Journal of Surgery, Vol. 178, No. 3, 1999, pp. 256-262. doi:10.1016/S0002-9610(99)00162-2

[14]   J. J. Mezhir, M. A. Shah, L. M. Jack, et al., “Positive Peritoneal Cytology in Patients with Gastric Cancer; Natural History and Outcome of 291 Patients,” Annals of Surgical Oncology, Vol. 17, No. 12, 2010, pp. 3173-3180. doi:10.1245/s10434-010-1183-0

[15]   S. Shimada, E. Tanaka, T. Marutsuka, et al., “Extensive Intraoperative Peritoneal Lavage and Chemotherapy for Gastric Cancer Patients with Peritoneal Free Cancer Cells,” Gastric Cancer, Vol. 5, No. 3, 2002, pp. 168-172. doi:10.1007/s101200200029

[16]   T. Marutsuka, S. Shimada, K. Shiomori, et al., “Mechanisms of Peritoneal Metastasis after Operation for Non-Serosa-Invasive Gastric Carcinoma: As Ultrarapid Detection System for Intraperitoneal Free Cancer Cells and a Prophylactic Strategy for Peritoneal Metastasis,” Clinical Cancer Research, Vol. 9, No. 2, 2003, pp. 678-685.

[17]   M. Kuramoto, S. Shimada, S. Ikeshima, et al., “Extensive Intraoperative Peritoneal Lavage as a Standard Prophylactic Strategy for Peritoneal Recurrence in Patients with Gastric Carcinoma,” Annals of Surgery, Vol. 250, No. 2, 2009, pp. 242-246. doi:10.1097/SLA.0b013e3181b0c80e

[18]   Y. Kodera, Y. Yamamura, Y. Shimizu, et al., “Peritoneal Washing Cytology: Prognostic Value of Positive Findings in Patients with Gastric Carcinoma Undergoing a Potentially Curative Resection,” Journal of Surgical Oncology, Vol. 72, No. 2, 1999, pp. 60-65. doi:10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>3.0.CO;2-1

[19]   R. Rosenberg, H. Nekarda, P. Bauer, et al., “Free Peritoneal Tumor Cells Are Independent Prognostic Factor in Curatively Resected Stage IB Gastric Carcinoma,” The British Journal of Surgery, Vol. 93, No. 3, 2006, pp. 325-331. doi:10.1002/bjs.5196

[20]   S. Fujimoto, M. Takahashi, T. Mutou, et al., “Successful Intraperitoneal Hyperthermic Chemoperfusion for the Prevention of Post Operative Peritoneal Recurrence in Patients with Advanced Gastric Carcinoma,” Cancer, Vol. 85, No. 3, 1999, pp. 529-534. doi:10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9

[21]   S. Abe, H. Yoshimura, H. Tabara, et al., “Curative Resection of Gastric Cancer: Limitation of Peritoneal Lavage Cytology in Predicting the Outcome,” Journal of Surgical Oncology, Vol. 59, No. 4, 1995, pp. 226-229. doi:10.1002/jso.2930590405

[22]   F. Bozzetti, G. Bonfani, A. Morabito, et al., “A Multifactorial Approach for the Prognosis of Patients with Carcinoma of the Stomach after Curative Resection,” Surgery, Gynecology & Obstetrics, Vol. 162, No. 3, 1986, pp. 229-234.

[23]   S. Shimada, Y. Yagi, K. Shiomori, et al., “Characterization and Proposal of the Optimal Therapeutic Strategy for Early Gastric Cancer,” Surgery, Vol. 129, No. 6, 2001, pp. 714-719. doi:10.1067/msy.2001.114217

[24]   J. J. Bonenkamp, I. Songun, M. Sasako, et al., “Randomised Comparison of Morbidity after D1 and D2 Dissection for Gastric Cancer in 996 Dutch Patients,” Lancet, Vol. 345, No. 8952, 1995, pp. 745-748. doi:10.1016/S0140-6736(95)90637-1

[25]   C. C. Wu, J. T. Chen, M. C. Chang, et al., “Optimal Surgical Strategy for Potentially Curable Serosa-Involved Gastric Carcinoma with Intraperitoneal Free Cancer Cells,” Journal of American College of Surgeons, Vol. 184, No. 6, 1997, pp. 611-617.

[26]   N. Hayes, J. Wayman, V. Wadehra, et al., “Peritoneal Cytology in the Surgical Evaluation of Gastric Carcinoma,” British Journal of Cancer, Vol. 79, No. 3-4, 1999, pp. 520-524. doi:10.1038/sj.bjc.6690081

[27]   Y. Yamamura, S. Ito, Y. Mochizuki, et al., “Distribution of Free Cancer Cells in the Abdominal Cavity Suggests Limitation of Bursectomy as an Essential Component of Radical Surgery for Gastric Carcinoma,” Gastric Cancer, Vol. 10, No. 1, 2007, pp. 24-28. doi:10.1007/s10120-006-0404-5

[28]   T. Mori, Y. Fujikawa, Y. Sugita, et al., “Application of Molecular Diagnosis for Detection of Peritoneal Micrometastasis and Evaluation of Preoperative Chemotherapy in Advanced Gastric Carcinoma,” Annals of Surgical Oncology, Vol. 11, No. 1, 2004, pp. 14-20. doi:10.1007/BF02524340

[29]   K. Maruyama, “The Most Important Prognostic Factors for Gastric Cancer Patients. A Study Using Univariate and Multivariate Analyses,” Scandinavian Journal of Gastroenterology, Vol. 22, No. 133, 1987, pp. 63-68. doi:10.3109/00365528709091021

[30]   Japanese Research Society for Gastric Cancer, “Japanese Classification of Gastric Carcinoma,” Kanehara, Tokyo, 1999.

[31]   L. E. Harrison, M. S. Karpeh, M. F. Brennan, et al., “Extended lymphadenectomy Is Associated with a Survival Benefit for Node-Negative Gastric Cancer,” Journal of Gastrointestinal Surgery, Vol. 2, No. 2, 1998, pp. 126-131. doi:10.1016/S1091-255X(98)80002-4

[32]   H. Zhang, C. Liu, D. Wu, et al., “Does D3 Surgery Offer a Better Survival Outcome Compared to D1 Surgery for Gastric Cancer? A Result Based on a Hospital Population of Two Decades as Taking D2 Surgery for Reference,” BMC Cancer, Vol. 10, No. 20, 2010, pp. 308. doi:10.1186/1471-2407-10-308

 
 
Top